Table 4.
Odds Ratios for Each Biomarker and Prostate Cancer Risk From Conditional Logistic Regression Analysesa, SU.VI.MAX Cohort, France, 1994–2007
| No. of Cases | No. of Controls | Unadjustedb Results |
Results From Multivariate Modelc |
Results From Multivariate Model Including All Studied Biomarkers |
||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | |||
| hs-CRP | ||||||||
| Q1 | 28 | 82 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 41 | 84 | 1.43 | 0.80, 2.56 | 1.76 | 0.84, 3.69 | 2.06 | 0.90, 4.71 |
| Q3 | 35 | 83 | 1.23 | 0.66, 2.31 | 1.70 | 0.77, 3.75 | 1.83 | 0.75, 4.48 |
| Q4 | 52 | 63 | 2.56 | 1.41, 4.65 | 2.52 | 1.18, 5.39 | 3.04 | 1.28, 7.23 |
| P for trend | 0.04 | 0.03 | 0.03 | |||||
| sICAM-1 | ||||||||
| Q1 | 39 | 82 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 43 | 82 | 1.10 | 0.65, 1.85 | 1.30 | 0.68, 2.52 | 1.19 | 0.56, 2.50 |
| Q3 | 37 | 75 | 1.03 | 0.59, 1.82 | 1.33 | 0.64, 2.76 | 1.10 | 0.49, 2.47 |
| Q4 | 37 | 73 | 1.07 | 0.62, 1.83 | 1.36 | 0.69, 2.69 | 1.00 | 0.43, 2.34 |
| P for trend | 0.9 | 0.4 | 0.8 | |||||
| sVCAM-1 | ||||||||
| Q1 | 35 | 72 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 39 | 79 | 1.02 | 0.58, 1.78 | 1.06 | 0.51, 2.20 | 0.85 | 0.36, 1.99 |
| Q3 | 42 | 83 | 1.04 | 0.60, 1.81 | 1.05 | 0.50, 2.22 | 0.86 | 0.36, 2.07 |
| Q4 | 40 | 78 | 1.05 | 0.61, 1.81 | 1.33 | 0.66, 2.71 | 1.16 | 0.50, 2.70 |
| P for trend | 0.8 | 0.4 | 0.6 | |||||
| Soluble E-selectin | ||||||||
| Q1 | 43 | 72 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 37 | 83 | 0.77 | 0.45, 1.29 | 0.81 | 0.41, 1.59 | 0.66 | 0.31, 1.42 |
| Q3 | 33 | 81 | 0.69 | 0.40, 1.20 | 0.80 | 0.41, 1.56 | 0.64 | 0.30, 1.35 |
| Q4 | 43 | 76 | 0.97 | 0.56, 1.65 | 1.22 | 0.61, 2.43 | 0.84 | 0.38, 1.88 |
| P for trend | 0.8 | 0.6 | 0.8 | |||||
| MCP-1 | ||||||||
| Q1 | 36 | 73 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 49 | 78 | 1.27 | 0.74, 2.19 | 1.13 | 0.58, 2.22 | 1.10 | 0.51, 2.36 |
| Q3 | 38 | 79 | 0.98 | 0.55, 1.74 | 0.87 | 0.42, 1.78 | 0.66 | 0.29, 1.50 |
| Q4 | 33 | 82 | 0.83 | 0.47, 1.46 | 0.59 | 0.29, 1.21 | 0.52 | 0.24, 1.14 |
| P for trend | 0.3 | 0.09 | 0.07 | |||||
| Leptin | ||||||||
| Q1 | 46 | 81 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 27 | 90 | 0.54 | 0.30, 0.96 | 0.47 | 0.22, 0.97 | 0.42 | 0.19, 0.95 |
| Q3 | 42 | 74 | 1.02 | 0.59, 1.76 | 0.89 | 0.44, 1.77 | 0.88 | 0.41, 1.91 |
| Q4 | 41 | 67 | 1.19 | 0.64, 2.22 | 0.69 | 0.27, 1.75 | 0.58 | 0.20, 1.68 |
| P for trend | 0.3 | 0.9 | 0.7 | |||||
| Adiponectin | ||||||||
| Q1 | 37 | 74 | 1 | Reference | 1 | Reference | 1 | Reference |
| Q2 | 39 | 84 | 0.92 | 0.54, 1.58 | 0.90 | 0.45, 1.80 | 0.78 | 0.37, 1.65 |
| Q3 | 40 | 81 | 0.99 | 0.57, 1.71 | 1.38 | 0.69, 2.76 | 1.36 | 0.63, 2.94 |
| Q4 | 40 | 73 | 1.10 | 0.64, 1.90 | 1.34 | 0.68, 2.61 | 1.18 | 0.56, 2.48 |
| P for trend | 0.7 | 0.3 | 0.1 | |||||
Abbreviations: CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein-1; OR, odds ratio; Q, quartile; sICAM-1, soluble intercellular adhesion molecule 1; SU.VI.MAX, Supplémentation en Vitamines et Minéraux Antioxydants; sVCAM-1, soluble vascular cell adhesion molecule 1.
a Cutoffs for male-specific quartiles were: hs-CRP—0.6, 1.1, 2.2; sICAM-1—199.0, 243.8, 288.0; sVCAM-1—532.6, 652.0, 786.0; soluble E-selectin—41.5, 30.6, 51.4; MCP-1—225.0, 267.0, 315.0; leptin—2.4, 4.1, 6.6; adiponectin—4.3, 6.4, 9.2. All statistical tests were 2-sided.
b Cases and controls were matched by sex, age, body mass index, and SU.VI.MAX intervention group.
c Adjusted for age, body mass index, height, SU.VI.MAX intervention group, alcohol intake, physical activity, smoking status, educational level, and baseline prostate-specific antigen level.